Potentiation of ATRA Activity in HL-60 Cells by Targeting Methylation Enzymes
Author(s) -
Ming C. Liau
Publication year - 2019
Publication title -
cytokines their relation with mineral dust induced diseases
Language(s) - English
Resource type - Journals
ISSN - 2639-5649
DOI - 10.24966/ppp-5649/100009
Subject(s) - retinoic acid , acute promyelocytic leukemia , cancer research , retinoic acid receptor , chemistry , histone deacetylase , leukemia , methyltransferase , promyelocytic leukemia protein , tretinoin , histone , methylation , biochemistry , biology , dna , immunology , gene
All Trans Retinoic Acid (ATRA) is a Differentiation Inducer (DI) of Acute Promyelocytic Leukemia (APL) with proven clinical utility. Its benefits for other types of Acute Myelocytic Leukemia (AML) have been limited. In APL, ATRA targets the PML-RARA (promyelocytic leukemia/retinoic acid receptor-alpha)/DNA methyltransferase (DNMT)/Histone Deacetylase (HDAC) complex, facilitating its
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom